2026: reflecting on the last year’s research progress and looking at what’s ahead
2025 was one of our most exciting years yet for Parkinson’s research. We saw the launch of EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, the start of recruitment for the phase 3 trial of ambroxol, the forging of new strategic partnerships, and much...
Learn more
New iLCT Pipeline study: Theracurmin
Cure Parkinson’s is excited to announce the funding of the fourth preclinical project as part of our iLCT Pipeline Research Acceleration Programme. Led by Dr Ayse Ulusoy at the German Center for Neurodegenerative Diseases (DNZE), this preclinical project will evaluate Theracurmin in models of Parkinson’s…
An update to our research strategy
Every few years, we set out to review and refresh our research strategy. This document underpins everything we do at Cure Parkinson’s and provides the roadmap for how we plan to move closer to our goal: to identify curative treatments for Parkinson’s, with urgency. As…
How a new study on Parkinson’s in the UK gives insights for research
Parkinson’s UK have recently published the results of their nationwide study, which looked at the prevalence of Parkinson’s in the UK. Information from studies like this help us identify gaps in Parkinson’s research and care. We use these insights to help demonstrate the urgent need…
EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, is now recruiting
Cure Parkinson’s is excited to announce that the first multi-arm multi-stage clinical trial platform for Parkinson’s in the UK – EJS ACT-PD – is underway, with recruitment now open to people with Parkinson’s. The Edmond J. Safra Accelerating Clinical Trials for Parkinson’s Disease (EJS ACT-PD)…
New funding opportunity: Combination therapies for Parkinson’s
Cure Parkinson’s is excited to announce that we are now accepting expressions of interest for our new combination therapy funding call. In August, Cure Parkinson’s announced we would be opening a £2 million funding call later this year to encourage the testing of combination therapies…